KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells

Prostate

Volumn 74, Issue 9, 2014, Pages 946-958

  Shen, Pengliang ^a   Sun, Jiabin ^b   Xu, Guiqin ^b   Zhang, Li ^b   Yang, Zhaojuan ^b   Xia, Suhua ^b   Wang, Yang ^a   Liu, Yongzhong ^b   Shi, Guowei ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

AKT; apoptosis; flutamide; Kruppel like factor 9; prostate cancer

Indexed keywords

ANDROGEN; ANDROSTANOLONE; CYCLIN A2; DOXYCYCLINE; FLUTAMIDE; KRUPPEL LIKE FACTOR 9; MESSENGER RNA; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY ASSAY; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; LNCAP CELL LINE; M PHASE CELL CYCLE CHECKPOINT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

AKT; APOPTOSIS; FLUTAMIDE; KRUPPEL-LIKE FACTOR 9; PROSTATE CANCER;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; FLUTAMIDE; HETEROGRAFTS; HUMANS; IN SITU NICK-END LABELING; KAPLAN-MEIER ESTIMATE; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 84901201313     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22812     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90.
2. Tammela TL,. Endocrine prevention and treatment of prostate cancer. Mol Cell Endocrinol 2012; 360 (1-2): 59-67.
3. Montalvo L, Carmena MJ, Bolanos O, Rodriguez-Henche N, Sanchez-Chapado M, Prieto JC,. Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells. Biosci Rep 2004; 24 (1): 11-21.
4. Anderson J,. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91 (5): 455-461.
5. Zhang M, Latham DE, Delaney MA, Chakravarti A,. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005; 24 (15): 2474-2482.
6. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45.
7. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC,. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000; 60 (24): 6841-6845.
8. McConnell BB, Yang VW,. Mammalian Kruppel-like factors in health and diseases. Physiol Rev 2010; 90 (4): 1337-1381.
9. Ohe N, Yamasaki Y, Sogawa K, Inazawa J, Ariyama T, Oshimura M, Fujii-Kuriyama Y,. Chromosomal localization and cDNA sequence of human BTEB, a GC box binding protein. Somat Cell Mol Genet 1993; 19 (5): 499-503.
10. Sporl F, Korge S, Jurchott K, Wunderskirchner M, Schellenberg K, Heins S, Specht A, Stoll C, Klemz R, Maier B, Wenck H, Schrader A, Kunz D, Blatt T, Kramer A,. Kruppel-like factor 9 is a circadian transcription factor in human epidermis that controls proliferation of keratinocytes. Proc Natl Acad Sci USA 2012; 109 (27): 10903-10908.
11. Pei H, Yao Y, Yang Y, Liao K, Wu JR,. Kruppel-like factor KLF9 regulates PPARgamma transactivation at the middle stage of adipogenesis. Cell Death Differ 2011; 18 (2): 315-327.
12. Kang L, Lu B, Xu J, Hu H, Lai M,. Downregulation of Kruppel-like factor 9 in human colorectal cancer. Pathol Int 2008; 58 (6): 334-338.
13. Ying M, Sang Y, Li Y, Guerrero-Cazares H, Quinones-Hinojosa A, Vescovi AL, Eberhart CG, Xia S, Laterra J,. Kruppel-like family of transcription factor 9, a differentiation-associated transcription factor, suppresses Notch1 signaling and inhibits glioblastoma-initiating stem cells. Stem Cells 2011; 29 (1): 20-31.
14. Wang J, Place RF, Huang V, Wang X, Noonan EJ, Magyar CE, Huang J, Li LC,. Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res 2010; 70 (24): 10182-10191.
15. Chen C, Bhalala HV, Vessella RL, Dong JT,. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 2003; 55 (2): 81-88.
16. Huang X, Li X, Guo B,. KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J Biol Chem 2008; 283 (44): 29795-29801.
17. He HJ, Gu XF, Xu WH, Yang DJ, Wang XM, Su Y,. Kruppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer. Acta Pharmacol Sin 2013; 34 (2): 282-288.
18. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, Friedman SL,. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001; 294 (5551): 2563-2566.
19. Chiam K, Ryan NK, Ricciardelli C, Day TK, Buchanan G, Ochnik AM, Murti K, Selth LA, Butler LM, Tilley WD, Bianco-Miotto T,. Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate 2013; 73 (2): 182-193.
20. Simmen RC, Pabona JM, Velarde MC, Simmons C, Rahal O, Simmen FA,. The emerging role of Kruppel-like factors in endocrine-responsive cancers of female reproductive tissues. J Endocrinol 2010; 204 (3): 223-231.
21. Toker A, Yoeli-Lerner M,. Akt signaling and cancer: Surviving but not moving on. Cancer Res 2006; 66 (8): 3963-3966.
22. Sarker D, Reid AH, Yap TA, de Bono JS,. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15 (15): 4799-4805.
23. Wong C, Kelce WR, Sar M, Wilson EM,. Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 1995; 270 (34): 19998-20003.
24. Wilding G, Chen M, Gelmann EP,. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989; 14 (2): 103-115.
25. Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, Zucker SN, Fink EE, Moparthy KC, Hu Q, Liu S, Boise LH, Lee KP, Nikiforov MA,. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 2012; 119 (6): 1450-1458.
26. Velarde MC, Zeng Z, McQuown JR, Simmen FA, Simmen RC,. Kruppel-like factor 9 is a negative regulator of ligand-dependent estrogen receptor alpha signaling in Ishikawa endometrial adenocarcinoma cells. Mol Endocrinol 2007; 21 (12): 2988-3001.
27. Befani CD, Vlachostergios PJ, Hatzidaki E, Patrikidou A, Bonanou S, Simos G, Papandreou CN, Liakos P,. Bortezomib represses HIF-1alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J Mol Med (Berl) 2012; 90 (1): 45-54.
28. Ayala G, Yan J, Li R, Ding Y, Thompson TC, Mims MP, Hayes TG, MacDonnell V, Lynch RG, Frolov A, Miles BJ, Wheeler TM, Harper JW, Tsai MJ, Ittmann MM, Kadmon D,. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res 2008; 14 (22): 7511-7518.
29. Sato A, Asano T, Ito K, Asano T,. Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells. J Urol 2012; 188 (6): 2410-2418.
30. Tsapakidis K, Vlachostergios PJ, Voutsadakis IA, Befani CD, Patrikidou A, Hatzidaki E, Daliani DD, Moutzouris G, Liakos P, Papandreou CN,. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. Int J Urol 2012; 19 (6): 565-574.
31. Mutter GL, Baak JP, Fitzgerald JT, Gray R, Neuberg D, Kust GA, Gentleman R, Gullans SR, Wei LJ, Wilcox M,. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 2001; 83 (2): 177-185.
32. Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S, Seitz S,. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci USA 2012; 109 (5): 1655-1660.
33. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung MC,. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000; 275 (11): 8027-8031.
34. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL,. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000; 275 (32): 24500-24505.